| 摘要: |
| ［摘要］ 白介素（IL）-37b是最近才被命名的白介素-1家族新成员,具有强大的抗炎作用。研究发现，动脉粥样硬化性疾病患者循环和斑块内IL-37b表达显著升高，与预后密切相关。动物实验表明，无论是内源性还是外源性IL-37b都具有显著的抗动脉粥样硬化作用。IL-37b可能成为动脉粥样硬化性疾病防治的新靶点。 |
| 关键词: 白介素-37b 炎症 动脉粥样硬化 |
| DOI：10.3969/j.issn.1674-3806.2019.05.02 |
| 分类号:R 543.5 |
| 基金项目:国家自然科学基金资助项目（编号：81560085） |
|
| IL-37b and atherosclerosis: from bench to bedside |
|
JI Qing-wei
|
|
Emergency & Critical Care Center, Beijing Anzhen Hospital Affiliated to Capital Medical University, Beijing 100029, China
|
| Abstract: |
| ［Abstract］ Interleukin-37b(IL-37b) is a novel anti-inflammatory cytokine in the interleukin-1 ligand family. Accumulating evidence has demonstrated that both circulating and local IL-37b levels are increased in the patients with atherosclerotic disease and associated with an adverse outcome, and some experimental studies have showed that both exogenous IL-37b and endogenous IL-37b protect mice from atherosclerosis, which indicates that IL-37b may be a novel therapeutic target in prevention and treatment of atherosclerotic disease. |
| Key words: Interleukin-37b(IL-37b) Inflammation Atherosclerosis |
